Leslie W.Bios Fund Ii Nt, L... Net Worth

The estimated Net Worth of Leslie W.Bios Fund Ii Nt, L... is at least $169 mil dollars as of 26 August 2022. Leslie L owns over 51,214 units of In8 Bio stock worth over $169,176 and over the last 3 years Leslie sold INAB stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Leslie L INAB stock SEC Form 4 insiders trading

Leslie has made over 2 trades of the In8 Bio stock since 2022, according to the Form 4 filled with the SEC. Most recently Leslie bought 51,214 units of INAB stock worth $103,452 on 26 August 2022.

The largest trade Leslie's ever made was buying 51,214 units of In8 Bio stock on 26 August 2022 worth over $103,452. On average, Leslie trades about 33,738 units every 3 days since 2021. As of 26 August 2022 Leslie still owns at least 559,076 units of In8 Bio stock.

You can see the complete history of Leslie L stock trades at the bottom of the page.

Insiders trading at In8 Bio

Over the last 3 years, insiders at In8 Bio have traded over $0 worth of In8 Bio stock and bought 5,038,673 units worth $10,468,296 . The most active insiders traders include Aaron G.L.Bios Equity Partn..., Leslie W.Bios Fund Ii Nt, L... y Emily Transcend Partners Op.... On average, In8 Bio executives and independent directors trade stock every 32 days with the average trade being worth of $63,860. The most recent stock trade was executed by Jeremy R. Graff on 13 September 2023, trading 2,500 units of INAB stock currently worth $2,375.

What does In8 Bio do?

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Complete history of Leslie L stock trades at In8 Bio

In8 Bio executives and stock owners

In8 Bio executives and other stock owners filed with the SEC include:

• William Ho,
  Co-Founder, Pres, CEO & Director
• Dr. Lawrence S. Lamb Ph.D.,
  Exec. VP, Co-Founder & Chief Scientific Officer
• Dr. Trishna Goswami M.D.,
  Chief Medical Officer
• Charles Butler,
  VP of Investor Relations & Communications
• Dr. Kate Rochlin Ph.D.,
  Chief Operating Officer
• Patrick McCall CPA,
  Chief Financial Officer
• Emily Fairbairn,
  
• Travis Whitfill,
  
• Jeremy R. Graff,
  
• Luba Greenwood,
  
• Alan S. Roemer,
  
• Corinne Epperly,
  
• Lawrence Lamb,
  EVP and CSO
• Leslie W.Bios Equity Partne...,
  
• Aaron G.L.Bios Fund Ii, Lpb...,
  
• Peter C. Brandt,
  
• William Tai Wei Ho,
  PRESIDENT AND CEO
• Aaron G.L.Bios Fund Iii, Lp...,
  
• Emily Transcend Partners Op...,
  
• Leslie W.Bios Fund Ii Nt, L...,
  
• Leslie W.Cavu Management, L...,
  
• Aaron G.L.Bios Capital Mana...,
  
• Leslie W.Bios Fund Ii Nt, L...,
  
• Aaron G.L.Bios Equity Partn...,
  
• Aaron G.L.Bios Fund Ii Nt, ...,
  
• Leslie W.Bios Equity Partne...,
  
• Kate Rochlin,
  Chief Operating Officer
• Patrick Mc Call,
  CHIEF FINANCIAL OFFICER
• Trishna Goswami,
  Chief Medical Officer